



ORIGINAL

Results of the modification of an acute pancreatitis management protocol in Intensive Care medicine [☆]



L. Amas Gómez ^{a,*}, F. Zubia Olaskoaga ^b

^a Servicio de Medicina Intensiva, Hospital Universitario Donostia, OSI Donostialdea, San Sebastián, Guipúzcoa, Spain

^b Servicio de Medicina Intensiva, Departamento de Medicina, Hospital Universitario Donostia, OSI Donostialdea, Euskal Herriko Unibertsitatea/ Universidad del País Vasco (UPV-EHU), San Sebastián, Guipúzcoa, Spain

Received 23 February 2018; accepted 14 May 2018

Available online 24 June 2019

KEYWORDS

Acute pancreatitis;
Clinical protocol;
Mortality;
Consensus
conference;
Clinical evolution

Abstract

Objective: To determine whether the implementation of a protocol for the management of patients with acute pancreatitis (AP) in an Intensive Care Unit (ICU) improves the clinical outcomes.

Design: A retrospective, before-after observational case series study was carried out.

Study period: 1 January 2001 to 31 December 2016, divided in 2 periods (pre-protocol 2001–2007, post-protocol 2008–2016).

Scope: An ICU with 48 beds and a recruitment population of 700,000 inhabitants.

Participants: AP patients admitted to the ICU, with no exclusion criteria.

Interventions: The recommendations proposed in the 7th Consensus Conference of the SEMICYUC on AP (5 September 2007) were applied in the second period.

Main variables of interest: Patient age, sex, APACHE II, SOFA, study period, pre-ICU hospital stay, nutrition, surgery, antibiotic prophylaxis, hospital mortality, ICU length of stay, hospital length of stay, determinant-based classification.

Results: The study comprised 286 patients (94 in the pre-protocol period, 192 in the post-protocol period), with a global in-hospital mortality rate of 23.1% ($n=66$). Application of the protocol decreased the pre-ICU hospital stay and the use of antibiotic prophylaxis, and increased the use of enteral nutrition. Hospital mortality decreased in the second period (35.1 vs. 17.18%; $P=.001$), with no significant changes in ICU and hospital stays. In the multivariate logistic regression analysis, the variable period of treatment remained as a variable of statistical significance in terms of hospital mortality (OR 0.34 for the period 2008–2016, 95% CI 0.15–0.74).

Conclusions: The implementation of a protocol could result in decreased mortality among AP patients admitted to the ICU.

© 2018 Elsevier España, S.L.U. and SEMICYUC. All rights reserved.

[☆] Please cite this article as: Amas Gómez L, Zubia Olaskoaga F. Resultados de la modificación de un protocolo de manejo para la pancreatitis aguda en Medicina Intensiva. Med Intensiva. 2019;43:546–555.

* Corresponding author.

E-mail address: leyre.amas@hotmail.com (L. Amas Gómez).

PALABRAS CLAVE

Pancreatitis aguda;
Protocolo;
Mortalidad;
Conferencia de
consenso;
Evolución clínica

Resultados de la modificación de un protocolo de manejo para la pancreatitis aguda en Medicina Intensiva**Resumen**

Objetivo: Conocer si la implantación de un protocolo para el manejo de la pancreatitis aguda (PA) en Medicina Intensiva (MI) redundó en la mejora de los resultados clínicos.

Diseño: Serie de casos, observacional, retrospectivo, con un diseño antes-después.

Periodo de estudio: 1/01/2001-31/12/2016, dividido en 2 periodos (preprotocolo 2001-2007; posprotocolo 2008-2016).

Ámbito: Un servicio de MI con 48 camas y población de 700.000 habitantes.

Participantes: Pacientes ingresados en MI con PA. No hubo criterios de exclusión.

Intervenciones: Se aplicaron las recomendaciones propuestas en la 7.^a Conferencia de Consenso (2007) de la SEMICYUC sobre la PA en el segundo periodo.

Variables de interés principales: Edad, sexo, APACHE II, SOFA, periodo a estudio, días previos al ingreso en MI, tipo de nutrición, cirugía, profilaxis antibiótica, mortalidad hospitalaria, estancia en MI, estancia hospitalaria, clasificación basada en determinantes.

Resultados: Doscientos ochenta y seis pacientes (94 preprotocolo, 192 posprotocolo), mortalidad hospitalaria de 66 casos (23,1%). La aplicación del protocolo supuso una disminución de la estancia hospitalaria previa al ingreso en MI, y de la profilaxis antibiótica, con un aumento del uso de nutrición enteral. Se evidenció un descenso de la mortalidad hospitalaria en el segundo periodo (35,1 vs. 17,18%, $p = 0,001$), sin cambios significativos en la estancia en MI ni en la hospitalaria. En el análisis multivariante, la variable «periodo de tratamiento» mantuvo significación estadística respecto a la mortalidad hospitalaria (OR 0,34 en 2008-2016, IC 95% 0,15-0,74).

Conclusiones: El establecimiento de un protocolo podría estar relacionado con un descenso de la mortalidad de los pacientes ingresados en MI por PA.

© 2018 Elsevier España, S.L.U. y SEMICYUC. Todos los derechos reservados.

Introduction

Acute pancreatitis (AP) is a potentially serious disease whose incidence has been growing¹ to up to 50 and 80 cases for every 100,000 inhabitants-year in the United States. This is why pancreatic disease is considered a common disease in children and adults alike.² Over half the cases in adults are associated with biliary disease and alcoholism. Its clinical course is variable and 80% of its forms of presentation are mild.^{3,4} However, the most serious cases can lead to mortality rates of up to 25–45% regardless of what the cause may be.⁵

Mortality has 2 peaks here: one early peak due to systemic inflammatory response syndrome (SIRS) that is severe compared to the development of pancreatic necrosis and multi organ failure, and a late peak due to infected pancreatic necrosis and/or sepsis.^{6,7} Being able to recognize early those patients with multi organ failure is essential to be able to guide resuscitation and start intensive treatment in an intensive care unit (ICU), thereby reducing morbimortality.⁸ As a matter of fact, an early stratification of the severity of the disease improves clinical results and reduces significantly the length of hospital stays.⁹

Back in 2007 SEMICYUC held the VII Consensus Conference on AP and established a series of recommendations for the comprehensive management of the disease. A few years later, in 2012, these recommendations¹⁰ were modified and the following changes were included:

- Early stratification of the severe forms of the disease with strict clinical and analytical follow-up during the first 48–96 h, and early ICU admission.
- Initiation of early artificial feeding (within the first 72 h) always using, if possible, enteral feeding through nasogastric probes, whether nasojejunal or transpyloric.¹¹
- The use of prophylactic antibiotic therapy is not recommended.
- Indicate surgical treatment basically for the management of infected pancreatic necrosis or abscess and delay the surgery for another 21 days to see what the clinical course of the disease is.¹²

This study tries to verify if the implementation of a protocol based on this Consensus Conference organized by SEMICYUC had an impact on the clinical progression of patients with AP admitted to ICUs. Therefore, we conducted one 16-year retrospective study before and after the implementation of a protocol based on these recommendations.

The primary endpoint of this study is to know whether the recommendations proposed at the VII Consensus Conference organized by SEMICYUC on the Management of Acute Pancreatitis in Intensive Medicine (05-09-07) had an impact on mortality, length of intra-ICU stays, and length of hospital stays in patients admitted to a critical care service due to AP; the study secondary endpoint was to evaluate whether such recommendations had an impact on the management of these patients when it comes to early ICU admissions,

use of early enteral feeding, non administration of empirical antibiotic therapy, and, if possible, delay surgery for another 21 days to see what the clinical course of the disease is.

Patients and methods

Primary endpoints: show whether the recommendations suggested at the VII Consensus Conference organized by SEMICYUC on the Management of Acute Pancreatitis in Intensive Medicine (05-09-07) had an impact on mortality, the length of ICU stays, and the length of hospital stays.

Secondary endpoints: assess whether the recommendations proposed at the VII Consensus Conference organized by SEMICYUC on the Management of Acute Pancreatitis in Intensive Medicine (05-09-07) changed the management of these patients.

Study design: observational, retrospective study designed before and after the VII Consensus Conference organized by SEMICYUC on the Management of Acute Pancreatitis in Intensive Medicine (05-09-07).

Population studied and reference setting: all patients admitted to the critical care service of Hospital Donostia due to AP were included consecutively and without any exclusion criteria. This critical care unit has 48 bed available and provides healthcare to a population of over 700 000 people.

Study periods: the study period was divided into two (2) periods. The first period from January 1, 2001 to December 31, 2016 and prior to the SEMICYUC Consensus Conference (between 2001 and 2007), and the second one after the SEMICYUC Consensus Conference between 2008 and 2016.

Variables: the following variables were collected in this study: affiliation variables (number of patients, age, sex); study period (pre-consensus conference or post-consensus conference); time of hospital admission (days of hospital admission-ICU admission, days of ICU stay, days of hospital stay); etiology that triggered the clinical signs (biliary, alcoholic, idiopathic, post-ERCP, other); degree of ultrasound-guided severity using the Balthasar score; severity scores including the SOFA and APACHE II scores within the first 24 h and Ranson's score; need for mechanical ventilation support (MVS) and continuous renal replacement therapy (CRRT); maximum intra-abdominal pressure (IAP) achieved during the ICU stay; feeding technique used in the patient within the first 48 h following admission (none, enteral, parenteral or mixed feeding); local complications developed by the patient during his hospital stay (infected necrosis, intra-abdominal hemorrhage, perforated hollow viscus), need for surgery; mortality and if mortality occurred why (early SIRS, pancreatic infection, nosocomial extrapancreatic infection, other); development of pancreatic sepsis; development of extrapancreatic sepsis; use of empirical antibiotic therapy at admission, and severity measured using the determinant-based classification.⁶

Definitions used in this study

- Days of hospital admission-ICU admission: days elapsed ever since the patient was admitted to the hospital until he was admitted to the intensive care unit.

- Period of treatment protocol: 2 different periods were established, pre- (2001–2007) and post- (2007–2016) consensus conference.
- Etiology:
 - Alcoholic: excessive consumption of alcohol (>60 g/day) sustained for over 5 years with no other defined cause for pancreatitis.
 - Biliary: presence of stones in the biliary duct with no other defined cause for pancreatitis.
 - Post-endoscopic retrograde cholangiopancreatography: pancreatitis that kicked in 7 days after performing one endoscopic retrograde cholangiopancreatography.
 - Other: other causes for pancreatitis including post-traumatic pancreatitis, postoperative pancreatitis, and hypertriglyceridemia-induced AP, apart from other less common causes.
 - Idiopathic: whenever the criteria for the remaining etiologies are not met.
- APACHE II and SOFA scores: maximum score obtained in the APACHE II and SOFA scores within the first 24 h after ICU admission.
- Local complications¹³: development, at any time and during hospital admission, of infected necrosis (defined as the presence of gas in the pancreatic tissue, a positive result in the Gram staining method or in samples obtained using the fine needle puncture-aspiration technique guided by imaging modalities, in surgical or drain samples), intra-abdominal hemorrhages (defined as the presence of a fluid collection of blood density as seen in the imaging modalities [CT scan, MRI], especially if active extravasation was confirmed after the administration of contrast or the direct visualization of the hemorrhage during surgery) or perforated hollow viscus (defined as a direct visualization during surgery or as the presence of some of the following findings in the imaging modalities: pneumoperitoneum, presence of grouped gas bubbles adjacent to the bowel loop wall, wall thickening, and loss of continuity or discontinuity in the bowel loop wall).
- Cause of death: early SIRS (patients who died due to AP-induced organ failure within the first seven days following hospital admission without any data indicative of infection in the pancreatic region), pancreatic infection (based on the definition of infected necrosis given in section "local complications"), local complications (intra-abdominal hemorrhages or perforated hollow viscus based on the previously described definitions [note that the cause of death defined as "local complications" did not include pancreatic infection which, due to its importance, is a well-differentiated cause *per se*^{6,7}]), and nosocomial extrapancreatic infections [an infection occurring during hospital admission that became evident 72 h or more after the patient's hospital admission and was not present when the patient was admitted to the hospital or during the incubation period]; this section included catheter-related infections, respiratory infections [mainly MVS-related pneumonias], and urinary tract infections. Infections were defined using the definitions established by SEMICYUC Infectious Diseases and Sepsis Working Group.^{14,15}
- Use of MVS: defined as the need for invasive mechanical ventilation at any time during the ICU stay.

- Use of CRRT: defined as the use of CRRT due to acute renal failure at any time during the ICU stay. During the first period of the protocol (2001–2007) the criteria for the use of CRRT were not well regulated and CRRT was started following orders from the treating physician. During the second period of the protocol (2008–2016) the *Failure* criterion proposed by the RIFLE classification¹⁶ was established the following protocol changes made at our ICU for all patients.
- Measurement of IAP: the IAP was measured using urinary catheters and based on the definitions established by the International Conference of Experts on Intra-abdominal Hypertension and Abdominal Compartment Syndrome.¹⁷ The highest value measured during the ICU stay was recorded.
- Need for surgery: defined according to SEMICYUC Consensus Conference on the management of AP from 2012.¹⁰ According to our hospital protocol, all surgeries performed on the pancreatic cell due to AP complications required the prior admission of the patient to the ICU. The main indications were these: infected necrosis or pancreatic abscess that could not be treated through minimally invasive step-up drainage approach, perforated hollow viscus, intra-abdominal hemorrhages that could not be treated using endovascular techniques, and abdominal compartmental syndrome that could not be treated with conservative treatment.

The management of sterile necrosis was initially conservative except for cases of 4-week duration and persistence of clinical symptoms.

Depending on when the surgery was performed, it was categorized as early surgery when performed less than 21 days after symptom onset, and late surgery when performed more than 21 days after symptom onset.

- Determinant-based classification⁴:

Mild acute pancreatitis: characterized by the lack of peripancreatic necrosis and organ failure.

Moderate acute pancreatitis: characterized by the presence of any type of peripancreatic sterile necrosis and transient organ failure.

Severe acute pancreatitis: characterized by the presence of any degree of infected peripancreatic necrosis or persistent organ failure.

Critical acute pancreatitis: characterized by the presence of infected peripancreatic necrosis and persistent organ failure.

Statistical analysis

We created one anonymous database with all the information from this study.

All data were analyzed according to the corresponding statistical methodology. The absolute and relative frequencies of qualitative variables were estimated. The quantitative variables that follow a normal distribution were expressed as mean and standard deviation. The qualitative variables that follow a non-parametric distribution, were expressed as mean and percentiles p25–p75.

Quantitative variables were compared using the Student's *t* test and means were compared using the analysis of variance (ANOVA) to compare the means. When variables were not normally distributed, the Kruskal–Wallis test or the Mann–Whitney-*U* test were used. Proportions were compared using the chi-square test or Fisher's exact test.

In order to determine the influence of the protocol used and the period of admission, and in an attempt to avoid any confounding factors, one univariate analysis was performed to know which factors impacted mortality. Afterwards, variables with *P* values < .1 were included in one multivariate logistic regression analysis. The lost values of the variables that were not picked were interpreted using the multiple imputation procedure.

Ethical and legal aspects

This study has been approved by the Guipuzkoa Clinical Trials Committee. Both the Organic Law 15/1999 on Personal Data Protection and the Royal Decree 994/1999 that passed a series of safety for of automatized files containing personal data were observed. The data from patients were collected anonymously from the electronic database using a numerical code. At no time data that may identify the patients were picked and there was no way of putting together their affiliation and clinical data.

Results

Two-hundred-and-eighty-six (286) patients were studied, 94 in the 2001–2007 period and 192 in the 2008–2016 period with a mean age of 59 years old, predominantly males with mainly biliary AP and a 23.07% overall mortality rate. [Table 1](#) shows the general characteristics of the patients included in the study.

Implementation of the protocol

The implementation of the protocol for the management of AP reduced the days prior to the ICU admission, increased the use of enteral feeding, and reduced the use of parenteral feeding and antibiotic prophylaxis. However, the rate of late surgeries did not go up (31.4 vs 26.4%, ns). [Table 2](#) shows the results obtained after the implementation of the protocol.

Clinical progression based on the study period

There were changes between both periods when it comes to the characteristics of the patients and the number of patients included in the study. During the second period, there was a larger number of patients hospitalized with lower Ranson's, APACHE II and SOFA scores within the first 24h with a higher degree of ultrasound-guided damage according to the Balthasar score. Similarly, the patients included in the second period showed a higher percentage of biliary AP, a lower maximum IAP, required less MVS, and had a pressing need for CRRT.

When it comes to clinical results, we can confirm a drop in the hospital mortality rate between both periods (35.1 vs 17.18%, *P* = .001) with a variation in the causes of

Table 1 Distribution of the sample general variables based on the study period (2001–2007 vs 2008–2016).

	Overall	2001–2007	2008–2016	P
<i>Number (%)</i>	286	94 (32.8)	192 (67.1)	
<i>Sex (male), n (%)</i>	193 (67.5)	62 (65.9)	131 (68.2)	ns
<i>Age (years), mean ± SD</i>	59.5 ± 15.3	58.3 ± 15.7	60.1 ± 15.2	ns
<i>Etiology, n (%)</i>				
Biliary	119 (41.3)	25 (26.6)	94 (48.4)	.015
Idiopathic	55 (19.2)	25 (26.6)	30 (15.6)	
Enolic	60 (21)	24 (25.5)	36 (18.7)	
Other	52 (18.2)	20 (21.3)	32 (16.7)	
<i>APACHE II, mean ± SD</i>	13.9 ± 6.2	15.5 ± 6.8	13.2 ± 5.7	.003
<i>SOFA, mean ± SD</i>	5.2 ± 3.4	7.1 ± 5.1	5.1 ± 3.3	.03
<i>Ranson's score, mean ± SD</i>	1.6 ± 1.1	1.9 ± 1.1	1.5 ± 0.9	.002
<i>Balthazar, mean ± SD</i>	6.6 ± 2.6	5.8 ± 2.5	7 ± 2.6	.001
<i>Maximum IAP (mmHg), mean ± SD</i>	21.1 ± 6.9	25.6 ± 7.1	19.8 ± 6.3	.003
<i>Local complications, n (%)</i>				
Intestinal perforation	18 (6.3)	5 (5.3)	13 (6.8)	ns
Abdominal hemorrhage	22 (7.7)	10 (10.6)	12 (6.3)	
Infected necrosis	112 (39.2)	31 (33.0)	81 (42.2)	
<i>Use of MVS, n (%)</i>	165 (57.7)	66 (69.4)	99 (51.6)	<.01
<i>Use of CRRT, n (%)</i>	87 (30.4)	19 (20)	68 (35.4)	<.01
<i>Determinant-based classification, n (%)</i>				
Moderate	69 (24.1)	17 (18.1)	52 (27.1)	ns
Severe	107 (37.4)	39 (41.5)	68 (35.4)	
Critical	110 (38.5)	38 (40.4)	72 (37.5)	

APACHE II, Acute Physiology and Chronic Health Evaluation II; CRRT, continuous renal replacement therapy; maximum IAP, maximum intra-abdominal pressure achieved during the ICU stay; MVS, mechanical ventilation support; ns, non-significant; SD, standard deviation; SOFA, Sequential Organ Failure Assessment.

Table 2 Distribution of the variables of the management protocol based on the study period (2001–2007 vs 2008–2016).

	2001–2007	2008–2016	P
<i>Days of hospital admission-ICU admission, mean (p25–p75)</i>	2 (1–7)	1 (1–3)	.033
<i>Type of early feeding (<48 h), n (%)</i>			
Parenteral	84 (89.5)	88 (45.9)	
Enteral	2 (2.1)	57 (29.7)	<.01
Mixed	0	7 (3.6)	
None	8 (8.5)	44 (22.9)	
<i>Antibiotic prophylaxis, n (%)</i>	80 (85.1)	67 (34.8)	<.01
<i>Surgical procedure, n (%)</i>	47 (50)	87 (45.3)	ns
<i>Day of procedure, mean (p25–p75)</i>	17 (7–28)	10 (3–25)	.015
<i>Late surgery (>21 days), n (%)</i>	30 (31.4)	52 (26.4)	ns

ICU, intensive care unit; ns, non-significant.

death: less extra-abdominal infections and early SIRS during the 2008–2016 period, and more local complications (intestinal perforations, intraabdominal hemorrhages) and other causes. The analysis of mortality following the determinant-based classification showed a significant drop in the subgroup of patients with severe AP (37 vs. 19.1%) during the 2008–2016 period. No other significant changes were seen with respect to the ICU stay or the hospital stay. [Table 3](#) shows a comparison of the results obtained between both periods.

Univariate and multivariate logistic regression analyses

As the methodology describes, one univariate analysis of the different quantitative and qualitative factors associated with mortality was performed in the first place ([Table 4](#)). The variables associated with mortality in a statistically significant way were age, the APACHE II score, IAP, the SOFA score, Ranson's score, the protocol period, etiology, the use of MVS and CRRT, and severity according to the determinant-based classification.

Table 3 Distribution of the variables of clinical progression based on the study period (2001–2007 vs 2008–2016).

	Overall	2001–2007	2008–2016	P
Hospital stay (days), mean (p25–p75)	31 (17–60)	34.5 (20–62)	30 (16–57)	Ns
ICU stay (days), mean (p25–p75)	11 (5–24)	12 (5–25)	11 (5–23)	Ns
Hospital mortality, n (%)	66 (23.1)	33 (35.1)	33 (17.2)	.001
Mortality causes, n (%)				
Early SIRS	4 (6.1)	4 (12.1)	0 (0)	.12
Pancreatic infection	19 (28.3)	10 (30.3)	9 (27.3)	
Local complications	27 (40.9)	9 (27.3)	18 (54.5)	
Extra-abdominal infection	7 (10.6)	5 (15.2)	2 (6.1)	
Other	9 (13.7)	5 (15.2)	4 (12.2)	
DBC-based hospital mortality, n (%)				
Moderate	1 (1.1)	1 (5.9)	0 (0)	Ns
Severe	28 (18.9)	15 (37)	13 (19.1)	.043
Critical	38 (33.9)	18 (47.4)	20 (27.8)	.057

DBC, determinant-based classification; ICU, intensive care unit; ns, non-significant; SIRS, systemic inflammatory response syndrome.

Then one multivariate logistic regression analysis was performed (Table 5). These were the variables that showed losses: maximum SOFA score within the first 24 h (87 cases, 30.4%), maximum IAP during the ICU stay (216 cases, 75.5%), body mass index (19 cases, 6.64%), the Balthazar score (6 cases, 2.10%), and Ranson's score (37 cases, 12.93%). The values lost were treated using the multiple imputation procedure to avoid excluding any cases, except for the IAP, that due to its high percentage of losses was eliminated right away from the multivariate analysis.

The period when the protocol was implemented showed a statistically significant correlation with mortality for those admissions occurring during the 2008–2016 period vs the 2001–2007 period (Table 5). Other factors associated in a statistically significant way were age, the APACHE II score, the use of MVS and not performing any surgeries. The Determinant-based Classification showed *P* values = .054 that were not considered statistically significant.

Discussion

This paper studied the clinical impact of implementing a protocol for the management of patients with AP who were admitted to an ICU based on SEMICYUC Consensus Conference from 2007.¹⁰ We studied a retrospective series of 286 patients with a high percentage of severe and critical forms of the disease according to the determinant-based classification.⁴ This is the largest series ever published to this day.

The recommendations established by the Consensus Conference described several issues with room for improvement on the management of patients with AP admitted to ICUs such as the use of early enteral feeding, early ICU admissions, delayed surgeries, and withdrawal of antibiotic prophylaxis. The degree of accomplishment of the study endpoints was significant with respect to early admissions, use of early enteral feeding,¹⁸ and withdrawal of antibiotic prophylaxis,^{19,20} except for late surgeries, which means that there is still room for improvement in our ICU. The protocolized monitoring of IAP was another improvement

included back in 2012 following changes in the SEMICYUC recommendations for that year,^{10,21} since its impact on the clinical progression of AP has been well-documented.^{22,23} However, since data mining was retrospective, there was a high percentage of cases where IAP could not be recorded so a decision was made not to include it as a result of the change in the management of patients or in the multivariate analysis either. The minimally invasive or zero invasive management of infected pancreatic necrosis started back in 2013¹² and it may have impacted the final outcomes, yet this was not specifically addressed in this study.

When it comes to the clinical outcomes, there were significant changes between 2001–2007 and 2008–2016: more cases, lower scores in severity markers, and a significant reduction of hospital mortality with changes in the causes of death. It is striking to see that there were no significant changes when it comes to the ICU and hospital stays between both periods. That is why data should be interpreted with caution. There was a 50% relative reduction of the mortality rate between both protocol periods, whereas the absolute hospital mortality rate was <20% in the second period. This mortality rate was much lower than the one described in other series: for instance, Bumbasirevic et al. described a 53.6% mortality rate in patients with AP admitted to ICUs⁹; one recent multicentric study conducted in 46 ICUs confirmed mortality rates of up to 28.7%.¹³ If we analyze the categories from the Determinant-based Classification, the decreased mortality rate observed was significant in the case of severe APs, whereas the mortality rate shown in this study by patients with severe and critical AP was lower compared to other series.^{24–28} It seems that this reduced mortality rate was due not only to more admissions of milder forms of the disease during the 2008–2016 period but also to a better management of these patients.

Similarly, there were changes in the causes of death since the mortality rate associated with extra-abdominal infections such as early SIRS was significantly reduced, while the mortality rate associated with local complications went up (intestinal perforations, intra-abdominal hemorrhages). We believe that early admission together with improved

Table 4 Univariate analysis of qualitative/quantitative variables with respect to hospital mortality.

Variable	Alive (n = 220)	Dead (n = 66)	P
Age (years), mean \pm SD	57.1 \pm 15.6	67.6 \pm 11.4	.000
Sex (male), n (%)	154 (70)	39 (59.1)	ns
Body mass index (kg/m ²), mean \pm SD	29.1 \pm 23.6	26.7 \pm 5.2	ns
Protocol period, n (%)			
2001–2007	61 (27.7)	33 (50)	
2008–2016	159 (72.3)	33 (50)	.001
Hospital-ICU days, mean (p25–p75)	2 (0–4)	1 (0.75–2)	ns
Etiology, n (%)			
Alcoholic	51 (23.2)	9 (13.6)	.017
Biliary	94 (42.7)	24 (36.4)	
Hyperlipidemia	14 (6.4)	3 (4.5)	
Idiopathic	32 (14.5)	23 (34.8)	
Post-ERCP	23 (10.5)	6 (9.1)	
Other	6 (2.7)	1 (1.5)	
Maximum APACHE II score within the first 24 h, mean \pm SD	12.3 \pm 5.2	19.8 \pm 6.2	.000
Maximum SOFA score within the first 24 h, mean \pm SD (lost values = 87 cases)	4.7 \pm 3.1	7.8 \pm 4.0	.000
Ranson's score, mean \pm SD	1.5 \pm 1.0	2.1 \pm 1.1	.000
CT scores (Balthazar), mean \pm SD	6.5 \pm 2.6	7.1 \pm 2.7	ns
Maximum IAP within the first 24 h (mmHg), mean \pm SD (lost values = 216 cases)	19.3 \pm 6.4	24.7 \pm 6.7	.002
Surgery, n (%)	97 (44.1)	37 (56.1)	ns
SP day, mean (p25–p75)	15 (4.5–27)	8 (2–20)	ns
Use of CRRT, n (%)	50 (22.7)	37 (56.1)	.000
Use of MVS, n (%)	106 (48.2)	59 (89.4)	.000
Feeding within the first 48 h, n (%)			
Parenteral	134 (60.9)	38 (57.6)	ns
Enteral	42 (19.1)	13 (19.7)	
Mixed	6 (2.7)	1 (1.5)	
None	38 (17.3)	14 (21.2)	
Local complications, n (%)			
Intestinal perforation	10 (4.5)	8 (12.1)	ns
Abdominal hemorrhage	15 (6.8)	7 (10.6)	ns
Infected necrosis	83 (37.7)	29 (43.9)	ns
Determinant-based classification, n (%)			
Moderate	68 (30.9)	1 (1.5)	
Severe	80 (36.4)	28 (42.4)	.000
Critical	72 (32.7)	37 (56.1)	

APACHE II, Acute Physiology and Chronic Health Evaluation II; CRRT, continuous renal replacement therapy; CT, computed tomography scan; IAP, intra-abdominal pressure; ICU, intensive care unit; MVS, mechanical ventilation support; ns, non-significant; Post-ERCP, post-endoscopic retrograde cholangiopancreatography; SD, standard deviation; SOFA, Sequential Organ Failure Assessment; SP day, surgical procedure day.

Table 5 Hospital mortality-adjusted multivariate analysis.

Variable	B	SE	Wald	df	OR (95%CI)	P
<i>Period 2008–2016</i>	–1.069	0.396	7.275	1	0.34 (0.15–0.74)	.007
<i>Maximum APACHE II score within the first 24 h</i>	0.162	0.038	17.765	1	1.17 (1.09–1.267)	.000
<i>Surgical procedure, no</i>	–1.563	0.597	6.856	1		.009
<i>Use of mechanical ventilation</i>	1.984	0.670	8.765	1	7.27 (1.95–27.04)	.003
<i>Age (years)</i>	0.044	0.017	7.005	1	1.04 (1.01–1.07)	.008
<i>Determinant-based classification</i>				2		.054
Moderate			5.822		1	
Severe	1.116	1.132	0.973		3.05 (0.33–28.06)	.324
Critical	2.219	1.199	3.423		9.19 (0.87–96.52)	.064

95%CI, 95% confidence interval; APACHE II, Acute Physiology and Chronic Health Evaluation II; df, degrees of freedom; MVS, mechanical ventilation support; OR, odds ratio; SE, standard error.

support measures may explain the lower mortality rate due to early SIRS as other authors have already described.^{9,29–31} When it comes to local complications, there were not significant changes in the percentage of patients who developed these complications between both periods or in the mortality rate, similar to what has already been reported by other series.^{30–32} However, there was a percentage gain in the overall mortality of patients who died due to intestinal perforations and intra-abdominal hemorrhages. The decrease of mortality rate due to early SIRS and extra-abdominal infections may have been a contributing factor together with how difficult it is to treat these complications, added to their late onset, in patients who already had significant organ damage, and infected necrosis previously treated on many occasions.

Since there may have been confounding factors that would explain the reduced mortality seen between both periods, one multivariate logistic regression analysis was conducted where the period of treatment was variable and significantly associated with hospital mortality. This multivariate analysis had several limitations particularly if we take into consideration that data were collected retrospectively. There were very few lost values, except for the maximum SOFA score within the first 24 h of the ICU stay that were handled using the multiple imputation procedure. As we have already said, the maximum IAP collected was excluded right away due to its high percentage of lost cases, which may have impacted the final outcomes.

Added to the retrospective nature of the study and the potential impact of the lost values, there were other limitations that make us be extra cautious when it comes to interpreting the good results coming from a lower mortality rate. As we said before, during the 2008–2016 period there was a change in the patients' clinical profile, with more patients and less severity according to the APACHE II, SOFA and Ranson scores and probably due to earlier admissions. Also, there were changes in the etiology of these patients, less use of MVS and greater use of CRRT. The greater use of CRRT had to do with general changes taking place in our ICU when the *Failure* criterion proposed by the RIFLE classification was established. Several studies confirm that the use of CRRT may reduce mortality in the most severe cases of AP, which may have impacted our results.^{33,34} Also, the long period of data mining and

its single-center nature may have impacted other general changes and in turn conditioned our own results; we are talking about something we may have missed in our study such as safety policies or campaigns for the reduction of nosocomial infections.^{35,36}

It would be interesting that the experience from our center were somehow validated by other hospitals or studied retrospectively in larger multicentric series and in a shorter period of time to see whether there is an improvement in the clinical progression of patients with AP admitted to ICUs.

Conclusions

The implementation of a protocol for the management of patients with AP admitted to ICUs based on the VII Consensus Conference organized by SEMICYUC resulted in better approaches for these patients when it comes to early ICU admissions, use of enteral feeding, and withdrawal of prophylactic antibiotic therapy. Also, all of this may have reduced hospital mortality.

Authors

Both Leyre Amas and Felix Zubia contributed to the processes of data mining, data analysis and interpretation, study design, and writing of the manuscript. Both of them approved the final version of this manuscript too.

Conflicts of interest

The authors declared no conflicts of interest whatsoever.

Acknowledgements

We wish to thank Gabriel Txoperena and Iñaki Arcega for their contribution in the statistical analysis and proofreading stage of this manuscript.

References

1. Bolado F, de-Madaria E. Novedades en el manejo de la pancreatitis aguda. *Gastroenterol Hepatol*. 2016;39 Suppl. 1:102–8.

2. Busireddy KK, Alobaidy M, Ramalho M, Kalubowila J, Baodong L, Santagostino I, et al. Pancreatitis-imaging approach. *World J Gastrointest Pathophysiol.* 2014;5:252–70.
3. Banks PA, Bollen TL, Dervenis C, Gooszen HG, Johnson CD, Sarr MG, et al. Classification of acute pancreatitis – 2012: revision of the Atlanta classification and definitions by international consensus. *Gut.* 2013;62:102–11.
4. Dellinger EP, Forsmark CE, Layer P, Lévy P, Maravi-Poma E, Petrov MS, et al. Determinant-based classification of acute pancreatitis severity: an international multidisciplinary consultation. *Ann Surg.* 2012;256:875–80.
5. Bumbasirevic V, Radenkovic D, Jankovic Z, Karamarkovic A, Jovanovic B, Milic N, et al. Severe acute pancreatitis: overall and early versus late mortality in intensive care units. *Pancreas.* 2009;38:122–5.
6. Petrov MS, Shanbhag S, Chakraborty M, Phillips AR, Windsor JA. Organ failure and infection of pancreatic necrosis as determinants of mortality in patients with acute pancreatitis. *Gastroenterology.* 2010;139:813–20.
7. Guo Q, Li A, Xia Q, Liu X, Tian B, Mai G, et al. The role of organ failure and infection in necrotizing pancreatitis: a prospective study. *Ann Surg.* 2014;259:1201–7.
8. Wu BU, Banks PA. Clinical management of patients with acute pancreatitis. *Gastroenterology.* 2013;144:1272–81.
9. Dimagno MJ, Wamsteker EJ, Rizk RS, Spaete JP, Gupta S, Sahay T, et al. A combined paging alert and web-based instrument alters clinician behavior and shortens hospital length of stay in acute pancreatitis. *Am J Gastroenterol.* 2014;109:306–15.
10. Maraví Poma E, Zubia Olascoaga F, Petrov MS, Navarro Soto S, Laplaza Santos C, Morales Alava F, et al. SEMICYUC 2012. Recommendations for intensive care management of acute pancreatitis. *Med Intensiva.* 2013;37:163–79.
11. Petrov MS, van Santvoort HC, Basselink MG, van der Heijden GJ, Windsor JA, Gooszen HG. Enteral nutrition and the risk of mortality and infectious complications in patients with severe acute pancreatitis: a meta-analysis of randomized trials. *Arch Surg.* 2008;143:1111–7.
12. Van Santvoort HC, Besselink MG, Bakker OJ, Hofker HS, Boermeester MA, Dejong CH, et al. A step-up approach or open necrosectomy for necrotizing pancreatitis. *N Engl J Med.* 2010;362:1491–502.
13. Zubia-Olascoaga F, Maraví-Poma E, Urreta-Barallobre I, Ramírez-Puerta MR, Mourelo-Fariña M, Marcos-Neira MP. Comparison between revised Atlanta classification and determinant-based classification for acute pancreatitis in Intensive Care Medicine. Why do not use a modified determinant-based classification? *Crit Care Med.* 2016;44:910–7.
14. European Centre for Disease Prevention and Control. Hospital in Europe Link for Infection Control through Surveillance (HELICS). Surveillance of Nosocomial Infections in Intensive Care Units. Protocol. Version 6.1. September 2004. Available from: <https://ecdc.europa.eu/sites/portal/files/media/en/publications/Publications/healthcare-associated-infections-HAI-ICU-protocol.pdf> [accessed 28.06.18].
15. Olaechea PM, Insausti J, Blanco A, Luque P. Epidemiology and impact of nosocomial infections. *Med Intensiva.* 2010;34:256–67.
16. Bellomo R, Ronco C, Kellum JA, Mehta RL, Palevsky P, Acute Dialysis Quality Initiative workgroup. Acute renal failure-definition, outcome measures, animal models, fluid therapy and information technology needs: The Second International Consensus Conference of the Acute Dialysis Quality Initiative (ADQI) Group. *Crit Care.* 2004;8:R204–12.
17. Malbrain ML, Cheatham ML, Kirkpatrick A, Sugrue M, Parr M, de Waele J, et al. Results from the international conference of experts on intra-abdominal hypertension and abdominal compartment syndrome. I. Definitions. *Intensive Care Med.* 2006;32:1722–32.
18. Bordejé Laguna L, Lorenzo Cárdenas C, Acosta Escribano J. Recomendaciones para el soporte nutricional y metabólico especializado del paciente crítico. Actualización. Consenso SEMICYUC-SENPE. Pancreatitis aguda grave. *Med Intensiva.* 2011;35 Suppl. 1:33–7.
19. Villatoro E, Bassi C, Larvin M. Tratamiento antibiótico para la profilaxis de la infección de la necrosis pancreática en la pancreatitis aguda (Revisión Cochrane traducida). In: *La Biblioteca Cochrane Plus.* Oxford: Update Software Ltd; 2008.
20. Maraví Poma E, Jiménez Urrea I, Arana E, Macaya L, Escuchuri J, Lozano O, et al. Antibióticos y pancreatitis aguda grave en Medicina Intensiva. Estado actual. Recomendaciones de la 7.ª Conferencia de Consenso de la SEMICYUC. *Med Intensiva.* 2008;32:78–80.
21. Maraví Poma E, Laplaza Santos C, Gorraiz López B, Albeniz Arbizu E, Zubia Olascoaga F, Petrov MS, et al. Hoja de ruta de los cuidados clínicos para la pancreatitis aguda: recomendaciones para el manejo anticipado multidisciplinar (*clinical pathways*). *Med Intensiva.* 2012;36:351–7.
22. Smit M, Buddingh KT, Bosma B, Nieuwenhuijs VB, Hofker HS, Zijlstra JG. Abdominal compartment syndrome and intra-abdominal ischemia in patients with severe acute pancreatitis. *World J Surg.* 2016;40:1454–61.
23. Marcos-Neira P, Zubia-Olascoaga F, López-Cuenca S, Bordejé-Laguna L. Relationship between intra-abdominal hypertension, outcome and the revised Atlanta and determinant-based classifications in acute pancreatitis. *BJs Open.* 2018;1:175–81.
24. Tee YS, Fang HY, Kuo IM, Lin YS, Huang SF, Yu MC. Serial evaluation of the SOFA score is reliable for predicting mortality in acute severe pancreatitis. *Medicine (Baltimore).* 2018;97:e9654, <http://dx.doi.org/10.1097/MD.0000000000009654>.
25. Zubia-Olascoaga F, Maraví-Poma E, Urreta-Barallobre I, Ramírez-Puerta MR, Mourelo-Fariña M, Marcos-Neira MP, et al. Development and validation of a multivariate prediction model for patients with acute pancreatitis in Intensive Care Medicine. *Pancreatol.* 2018;18:161–7.
26. Ignatavicius P, Gulla A, Cernauskis K, Barauskas G, Dambrauskas Z. How severe is moderately severe acute pancreatitis? Clinical validation of revised 2012 Atlanta Classification. *World J Gastroenterol.* 2017;23:7785–90.
27. Nawaz H, Mounzer R, Yadav D, Yabes JG, Slivka A, Whitcomb DC, et al. Revised Atlanta and determinant-based classification: application in a prospective cohort of acute pancreatitis patients. *Am J Gastroenterol.* 2013;108:1911–7.
28. Choi JH, Kim MH, Cho DH, Oh D, Lee HW, Song TJ, et al. Revised Atlanta classification and determinant-based classification: which one better at stratifying outcomes of patients with acute pancreatitis? *Pancreatol.* 2017;17:194–200.
29. Gloor B, Müller CA, Worni M, Martignoni ME, Uhl W, Büchler MW. Late mortality in patients with severe acute pancreatitis. *Br J Surg.* 2001;88:975–9.
30. Carnovale A, Rabitti PG, Manes G, Esposito P, Pacelli L, Uomo G. Mortality in acute pancreatitis: is it an early or a late event? *JOP.* 2005;6:438–44.
31. Fu CY, Yeh CN, Hsu JT, Jan YY, Hwang TL. Timing of mortality in severe acute pancreatitis: experience from 643 patients. *World J Gastroenterol.* 2007;13:1966–9.

32. Shen X, Sun J, Zhang J, Ke L, Tong Z, Li G, et al. Risk Factors and outcome for massive intra-abdominal bleeding among patients with infected necrotizing pancreatitis. *Medicine (Baltimore)*. 2015;94:e1172.
33. Cui HX, Xu JY, Li MQ. Efficacy of continuous renal replacement therapy in the treatment of severe acute pancreatitis associated acute respiratory distress syndrome. *Eur Rev Med Pharmacol Sci*. 2014;18:2523–6.
34. Wu C, Wang X, Jiang T, Li W, Li N, Li J. Improved effect of continuous renal replacement therapy in metabolic status and body composition of early phase of acute pancreatitis. *Int J Artif Organs*. 2015;38:523–9.
35. Álvarez-Lerma F, Palomar-Martínez M, Sánchez-García M, Martínez-Alonso M, Álvarez-Rodríguez J, Lorente L, et al. Prevention of ventilator-associated pneumonia: the multimodal approach of the Spanish ICU ‘‘Pneumonia Zero’’ program. *Crit Care Med*. 2018;46:181–8.
36. Álvarez-Lerma F, Oliva G, Ferrer JM, Riera A, Palomar M, Consell Assessor del Proyecto Bacteriemia Zero en Catalunya. Resultados de la aplicación del proyecto Bacteriemia Zero en Catalunya. *Med Clin (Barc)*. 2014;143 Suppl. 1:11–6.